CyberKnife stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study.
Fiche publication
Date publication
septembre 2023
Journal
Journal of thoracic disease
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier, Dr FAIVRE Jean-Christophe
Tous les auteurs :
Oudin V, Salleron J, Marchesi V, Peiffert D, Khadige M, Faivre JC
Lien Pubmed
Résumé
Few studies have investigated whether there is a difference in local control or overall survival rates following treatment with robotic stereotactic body radiation therapy (SBRT) with or without prior fiducial marker implantation. Our study aimed to investigate this in patients with primary or secondary lung tumors.
Mots clés
Cyberknife®, Real-time tracking, fiducial markers, lung cancer, stereotactic radiotherapy
Référence
J Thorac Dis. 2023 09 28;15(9):4636-4647